Citigroup
EGRX

Citigroup’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Citigroup’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000,389
Closed -$3.73M – 6058
2024
Q3 		$3.73M Sell
1,000,389
-1,166
-0.1% -$5.56K ﹤0.01% 2097
2024
Q2 		$5.61M Buy
1,001,555
+998,837
+36,749% +$4.35M ﹤0.01% 1554
2024
Q1 		$14.2K Buy
2,718
+972
+56% +$5.33K ﹤0.01% 5120
2023
Q4 		$9.13K Buy
1,746
+1,543
+760% +$15.2K ﹤0.01% 5212
2023
Q3 		$3.2K Sell
203
-5,834
-97% -$105K ﹤0.01% 4840
2023
Q2 		$117K Sell
6,037
-1,375
-19% -$32.6K ﹤0.01% 4167
2023
Q1 		$210K Sell
7,412
-26,366
-78% -$783K ﹤0.01% 3706
2022
Q4 		$987K Sell
33,778
-24,613
-42% -$783K ﹤0.01% 2613
2022
Q3 		$1.54M Buy
58,391
+31,113
+114% +$1.14M ﹤0.01% 2352
2022
Q2 		$1.21M Buy
27,278
+11,172
+69% +$513K ﹤0.01% 2492
2022
Q1 		$797K Sell
16,106
-19,690
-55% -$945K ﹤0.01% 3158
2021
Q4 		$1.82M Buy
35,796
+14,539
+68% +$753K ﹤0.01% 2702
2021
Q3 		$1.19M Sell
21,257
-21,105
-50% -$1.04M ﹤0.01% 2959
2021
Q2 		$1.81M Sell
42,362
-337
-0.8% -$13.9K ﹤0.01% 2737
2021
Q1 		$1.78M Buy
42,699
+35,394
+485% +$1.64M ﹤0.01% 2573
2020
Q4 		$340K Sell
7,305
-39
-0.5% -$1.82K ﹤0.01% 4552
2020
Q3 		$312K Sell
7,344
-9,879
-57% -$432K ﹤0.01% 4253
2020
Q2 		$826K Buy
17,223
+3,955
+30% +$197K ﹤0.01% 3763
2020
Q1 		$610K Buy
13,268
+5,659
+74% +$284K ﹤0.01% 3683
2019
Q4 		$457K Sell
7,609
-11,255
-60% -$671K ﹤0.01% 4495
2019
Q3 		$1.07M Buy
18,864
+13,762
+270% +$774K ﹤0.01% 3576
2019
Q2 		$284K Sell
5,102
-847
-14% -$44.2K ﹤0.01% 4967
2019
Q1 		$301K Sell
5,949
-106,029
-95% -$4.72M ﹤0.01% 4704
2018
Q4 		$4.51M Buy
111,978
+64,193
+134% +$3.31M ﹤0.01% 1901
2018
Q3 		$3.31M Buy
47,785
+10,405
+28% +$789K ﹤0.01% 2253
2018
Q2 		$2.83M Sell
37,380
-9,453
-20% -$595K ﹤0.01% 2382
2018
Q1 		$2.47M Buy
46,833
+1,806
+4% +$105K ﹤0.01% 2417
2017
Q4 		$2.4M Sell
45,027
-3,995
-8% -$222K ﹤0.01% 2489
2017
Q3 		$2.92M Buy
49,022
+15,380
+46% +$930K ﹤0.01% 2263
2017
Q2 		$2.65M Buy
33,642
+14,218
+73% +$1.16M ﹤0.01% 2294
2017
Q1 		$1.61M Sell
19,424
-54,855
-74% -$4.08M ﹤0.01% 2688
2016
Q4 		$5.89M Buy
74,279
+66,303
+831% +$4.82M 0.01% 1652
2016
Q3 		$559K Buy
7,976
+7,671
+2,515% +$425K ﹤0.01% 3802
2016
Q2 		$12K Sell
305
-5,759
-95% -$240K ﹤0.01% 6463
2016
Q1 		$246K Buy
6,064
+5,004
+472% +$317K ﹤0.01% 4884
2015
Q4 		$94K Sell
1,060
-4,866
-82% -$384K ﹤0.01% 5424
2015
Q3 		$439K Buy
5,926
+5,815
+5,239% +$484K ﹤0.01% 3869
2015
Q2 		$9K Buy
+111
New +$7.23K ﹤0.01% 6529
2014
Q4 		– Sell
-14
Closed – – 7366
2014
Q3 		$0 Buy
+14
New +$174 ﹤0.01% 7344

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Citigroup's EGRX Position: Q4 2024 in Review

Citigroup sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 1,000,389 shares — an estimated $3.73M sold.

Citigroup first reported a position in EGRX in Q3 2014 and held it in 39 quarters. The position peaked at $5.89M in Q4 2016. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Citigroup reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Citigroup sold 1,000,389 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $3.73M.
  • Citigroup first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and held it in 39 quarters.
  • Citigroup's Eagle Pharmaceuticals, Inc. position peaked at $5.89M in Q4 2016.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Citigroup's 13F filing for Q4 2024, filed 12 Feb 2025.